APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-Obesity Prescription

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Anti-Obesity Prescription Market Analysis and Forecast 2026-2032

22 December 2025194 pages

Choose your research edition.

Industry ResearchAnti-Obesity Prescription Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-Obesity Prescription Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Anti-Obesity Prescription Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-Obesity Prescription Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-Obesity Prescription Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Anti-Obesity Prescription market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Anti-Obesity Prescription is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Anti-Obesity Prescription is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Anti-Obesity Prescription is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Anti-Obesity Prescription is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Anti-Obesity Prescription include Akrimax Pharmaceuticals, Alpex Pharma, Arena Pharmaceuticals, Arrowhead Research, Bridge BioResearch, Compellis Pharmaceuticals, Yungjin Pharm, Zealand Pharma and Zydus Cadila, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Anti-Obesity Prescription, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Anti-Obesity Prescription, also provides the sales of main regions and countries. Of the upcoming market potential for Anti-Obesity Prescription, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Anti-Obesity Prescription sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Anti-Obesity Prescription market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Anti-Obesity Prescription sales, projected growth trends, production technology, application and end-user industry.

Anti-Obesity Prescription Segment by Company

Akrimax Pharmaceuticals

Alpex Pharma

Arena Pharmaceuticals

Arrowhead Research

Bridge BioResearch

Compellis Pharmaceuticals

Yungjin Pharm

Zealand Pharma

Zydus Cadila

Anti-Obesity Prescription Segment by Type

Lorcaserin

Liraglutide

Phentermine and Topiramate

Orlistat

Bupropion and Naltrexone

Anti-Obesity Prescription Segment by Application

E-Commerce

Retail Pharmacies

Hospital Pharmacies

Anti-Obesity Prescription Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Obesity Prescription market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-Obesity Prescription and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Obesity Prescription.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Anti-Obesity Prescription in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Anti-Obesity Prescription manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-Obesity Prescription sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Anti-Obesity Prescription Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Lorcaserin Major Manufacturers Table 3. Liraglutide Major Manufacturers Table 4. Phentermine and Topiramate Major Manufacturers Table 5. Orlistat Major Manufacturers Table 6. Bupropion and Naltrexone Major Manufacturers Table 7. Global Anti-Obesity Prescription Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. E-Commerce Major Manufacturers Table 9. Retail Pharmacies Major Manufacturers Table 10. Hospital Pharmacies Major Manufacturers Table 11. Anti-Obesity Prescription Industry Trends Table 12. Anti-Obesity Prescription Industry Drivers Table 13. Anti-Obesity Prescription Industry Opportunities and Challenges Table 14. Anti-Obesity Prescription Industry Restraints Table 15. Global Anti-Obesity Prescription Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 16. Global Anti-Obesity Prescription Revenue by Region (2021-2026) & (US$ Million) Table 17. Global Anti-Obesity Prescription Revenue by Region (2027-2032) & (US$ Million) Table 18. Global Anti-Obesity Prescription Revenue Market Share by Region (2021-2026) Table 19. Global Anti-Obesity Prescription Revenue Market Share by Region (2027-2032) Table 20. Global Anti-Obesity Prescription Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 21. Global Anti-Obesity Prescription Sales by Region (2021-2026) & (k units) Table 22. Global Anti-Obesity Prescription Sales by Region (2027-2032) & (k units) Table 23. Global Anti-Obesity Prescription Sales Market Share by Region (2021-2026) Table 24. Global Anti-Obesity Prescription Sales Market Share by Region (2027-2032) Table 25. Global Anti-Obesity Prescription Revenue by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Anti-Obesity Prescription Revenue Market Share by Manufacturers (2021-2026) Table 27. Global Anti-Obesity Prescription Sales by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Anti-Obesity Prescription Sales Market Share by Manufacturers (2021-2026) Table 29. Global Anti-Obesity Prescription Sales Price (US$/unit) of Manufacturers (2021-2026) Table 30. Global Anti-Obesity Prescription Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 31. Global Anti-Obesity Prescription Key Manufacturers Manufacturing Sites & Headquarters Table 32. Global Anti-Obesity Prescription Manufacturers, Product Type & Application Table 33. Global Anti-Obesity Prescription Manufacturers' Establishment Date Table 34. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global Anti-Obesity Prescription by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global Anti-Obesity Prescription Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Anti-Obesity Prescription Revenue by Type (2021-2026) & (US$ Million) Table 38. Global Anti-Obesity Prescription Revenue by Type (2027-2032) & (US$ Million) Table 39. Global Anti-Obesity Prescription Revenue Market Share by Type (2021-2026) Table 40. Global Anti-Obesity Prescription Revenue Market Share by Type (2027-2032) Table 41. Global Anti-Obesity Prescription Sales by Type 2021 VS 2025 VS 2032 (k units) Table 42. Global Anti-Obesity Prescription Sales by Type (2021-2026) & (k units) Table 43. Global Anti-Obesity Prescription Sales by Type (2027-2032) & (k units) Table 44. Global Anti-Obesity Prescription Sales Market Share by Type (2021-2026) Table 45. Global Anti-Obesity Prescription Sales Market Share by Type (2027-2032) Table 46. Global Anti-Obesity Prescription Price by Type (2021-2026) & (US$/unit) Table 47. Global Anti-Obesity Prescription Price by Type (2027-2032) & (US$/unit) Table 48. Global Anti-Obesity Prescription Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Anti-Obesity Prescription Revenue by Application (2021-2026) & (US$ Million) Table 50. Global Anti-Obesity Prescription Revenue by Application (2027-2032) & (US$ Million) Table 51. Global Anti-Obesity Prescription Revenue Market Share by Application (2021-2026) Table 52. Global Anti-Obesity Prescription Revenue Market Share by Application (2027-2032) Table 53. Global Anti-Obesity Prescription Sales by Application 2021 VS 2025 VS 2032 (k units) Table 54. Global Anti-Obesity Prescription Sales by Application (2021-2026) & (k units) Table 55. Global Anti-Obesity Prescription Sales by Application (2027-2032) & (k units) Table 56. Global Anti-Obesity Prescription Sales Market Share by Application (2021-2026) Table 57. Global Anti-Obesity Prescription Sales Market Share by Application (2027-2032) Table 58. Global Anti-Obesity Prescription Price by Application (2021-2026) & (US$/unit) Table 59. Global Anti-Obesity Prescription Price by Application (2027-2032) & (US$/unit) Table 60. Akrimax Pharmaceuticals Company Information Table 61. Akrimax Pharmaceuticals Business Overview Table 62. Akrimax Pharmaceuticals Anti-Obesity Prescription Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 63. Akrimax Pharmaceuticals Anti-Obesity Prescription Product Portfolio Table 64. Akrimax Pharmaceuticals Recent Development Table 65. Alpex Pharma Company Information Table 66. Alpex Pharma Business Overview Table 67. Alpex Pharma Anti-Obesity Prescription Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 68. Alpex Pharma Anti-Obesity Prescription Product Portfolio Table 69. Alpex Pharma Recent Development Table 70. Arena Pharmaceuticals Company Information Table 71. Arena Pharmaceuticals Business Overview Table 72. Arena Pharmaceuticals Anti-Obesity Prescription Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. Arena Pharmaceuticals Anti-Obesity Prescription Product Portfolio Table 74. Arena Pharmaceuticals Recent Development Table 75. Arrowhead Research Company Information Table 76. Arrowhead Research Business Overview Table 77. Arrowhead Research Anti-Obesity Prescription Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Arrowhead Research Anti-Obesity Prescription Product Portfolio Table 79. Arrowhead Research Recent Development Table 80. Bridge BioResearch Company Information Table 81. Bridge BioResearch Business Overview Table 82. Bridge BioResearch Anti-Obesity Prescription Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. Bridge BioResearch Anti-Obesity Prescription Product Portfolio Table 84. Bridge BioResearch Recent Development Table 85. Compellis Pharmaceuticals Company Information Table 86. Compellis Pharmaceuticals Business Overview Table 87. Compellis Pharmaceuticals Anti-Obesity Prescription Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Compellis Pharmaceuticals Anti-Obesity Prescription Product Portfolio Table 89. Compellis Pharmaceuticals Recent Development Table 90. Yungjin Pharm Company Information Table 91. Yungjin Pharm Business Overview Table 92. Yungjin Pharm Anti-Obesity Prescription Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Yungjin Pharm Anti-Obesity Prescription Product Portfolio Table 94. Yungjin Pharm Recent Development Table 95. Zealand Pharma Company Information Table 96. Zealand Pharma Business Overview Table 97. Zealand Pharma Anti-Obesity Prescription Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Zealand Pharma Anti-Obesity Prescription Product Portfolio Table 99. Zealand Pharma Recent Development Table 100. Zydus Cadila Company Information Table 101. Zydus Cadila Business Overview Table 102. Zydus Cadila Anti-Obesity Prescription Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Zydus Cadila Anti-Obesity Prescription Product Portfolio Table 104. Zydus Cadila Recent Development Table 105. North America Anti-Obesity Prescription Revenue by Type (2021-2026) & (US$ Million) Table 106. North America Anti-Obesity Prescription Revenue by Type (2027-2032) & (US$ Million) Table 107. North America Anti-Obesity Prescription Sales by Type (2021-2026) & (k units) Table 108. North America Anti-Obesity Prescription Sales by Type (2027-2032) & (k units) Table 109. North America Anti-Obesity Prescription Sales Price by Type (2021-2026) & (US$/unit) Table 110. North America Anti-Obesity Prescription Sales Price by Type (2027-2032) & (US$/unit) Table 111. North America Anti-Obesity Prescription Revenue by Application (2021-2026) & (US$ Million) Table 112. North America Anti-Obesity Prescription Revenue by Application (2027-2032) & (US$ Million) Table 113. North America Anti-Obesity Prescription Sales by Application (2021-2026) & (k units) Table 114. North America Anti-Obesity Prescription Sales by Application (2027-2032) & (k units) Table 115. North America Anti-Obesity Prescription Sales Price by Application (2021-2026) & (US$/unit) Table 116. North America Anti-Obesity Prescription Sales Price by Application (2027-2032) & (US$/unit) Table 117. North America Anti-Obesity Prescription Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. North America Anti-Obesity Prescription Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 119. North America Anti-Obesity Prescription Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 120. North America Anti-Obesity Prescription Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 121. North America Anti-Obesity Prescription Sales by Country (2021-2026) & (k units) Table 122. North America Anti-Obesity Prescription Sales by Country (2027-2032) & (k units) Table 123. North America Anti-Obesity Prescription Sales Price by Country (2021-2026) & (US$/unit) Table 124. North America Anti-Obesity Prescription Sales Price by Country (2027-2032) & (US$/unit) Table 125. United States Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 126. Canada Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 127. Mexico Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 128. Europe Anti-Obesity Prescription Revenue by Type (2021-2026) & (US$ Million) Table 129. Europe Anti-Obesity Prescription Revenue by Type (2027-2032) & (US$ Million) Table 130. Europe Anti-Obesity Prescription Sales by Type (2021-2026) & (k units) Table 131. Europe Anti-Obesity Prescription Sales by Type (2027-2032) & (k units) Table 132. Europe Anti-Obesity Prescription Sales Price by Type (2021-2026) & (US$/unit) Table 133. Europe Anti-Obesity Prescription Sales Price by Type (2027-2032) & (US$/unit) Table 134. Europe Anti-Obesity Prescription Revenue by Application (2021-2026) & (US$ Million) Table 135. Europe Anti-Obesity Prescription Revenue by Application (2027-2032) & (US$ Million) Table 136. Europe Anti-Obesity Prescription Sales by Application (2021-2026) & (k units) Table 137. Europe Anti-Obesity Prescription Sales by Application (2027-2032) & (k units) Table 138. Europe Anti-Obesity Prescription Sales Price by Application (2021-2026) & (US$/unit) Table 139. Europe Anti-Obesity Prescription Sales Price by Application (2027-2032) & (US$/unit) Table 140. Europe Anti-Obesity Prescription Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 141. Europe Anti-Obesity Prescription Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 142. Europe Anti-Obesity Prescription Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 143. Europe Anti-Obesity Prescription Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 144. Europe Anti-Obesity Prescription Sales by Country (2021-2026) & (k units) Table 145. Europe Anti-Obesity Prescription Sales by Country (2027-2032) & (k units) Table 146. Europe Anti-Obesity Prescription Sales Price by Country (2021-2026) & (US$/unit) Table 147. Europe Anti-Obesity Prescription Sales Price by Country (2027-2032) & (US$/unit) Table 148. Germany Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 149. France Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 150. U.K. Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 151. Italy Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 152. Russia Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 153. Spain Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 154. Netherlands Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 155. Switzerland Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 156. Sweden Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 157. Poland Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 158. China Anti-Obesity Prescription Revenue by Type (2021-2026) & (US$ Million) Table 159. China Anti-Obesity Prescription Revenue by Type (2027-2032) & (US$ Million) Table 160. China Anti-Obesity Prescription Sales by Type (2021-2026) & (k units) Table 161. China Anti-Obesity Prescription Sales by Type (2027-2032) & (k units) Table 162. China Anti-Obesity Prescription Sales Price by Type (2021-2026) & (US$/unit) Table 163. China Anti-Obesity Prescription Sales Price by Type (2027-2032) & (US$/unit) Table 164. China Anti-Obesity Prescription Revenue by Application (2021-2026) & (US$ Million) Table 165. China Anti-Obesity Prescription Revenue by Application (2027-2032) & (US$ Million) Table 166. China Anti-Obesity Prescription Sales by Application (2021-2026) & (k units) Table 167. China Anti-Obesity Prescription Sales by Application (2027-2032) & (k units) Table 168. China Anti-Obesity Prescription Sales Price by Application (2021-2026) & (US$/unit) Table 169. China Anti-Obesity Prescription Sales Price by Application (2027-2032) & (US$/unit) Table 170. Asia Anti-Obesity Prescription Revenue by Type (2021-2026) & (US$ Million) Table 171. Asia Anti-Obesity Prescription Revenue by Type (2027-2032) & (US$ Million) Table 172. Asia Anti-Obesity Prescription Sales by Type (2021-2026) & (k units) Table 173. Asia Anti-Obesity Prescription Sales by Type (2027-2032) & (k units) Table 174. Asia Anti-Obesity Prescription Sales Price by Type (2021-2026) & (US$/unit) Table 175. Asia Anti-Obesity Prescription Sales Price by Type (2027-2032) & (US$/unit) Table 176. Asia Anti-Obesity Prescription Revenue by Application (2021-2026) & (US$ Million) Table 177. Asia Anti-Obesity Prescription Revenue by Application (2027-2032) & (US$ Million) Table 178. Asia Anti-Obesity Prescription Sales by Application (2021-2026) & (k units) Table 179. Asia Anti-Obesity Prescription Sales by Application (2027-2032) & (k units) Table 180. Asia Anti-Obesity Prescription Sales Price by Application (2021-2026) & (US$/unit) Table 181. Asia Anti-Obesity Prescription Sales Price by Application (2027-2032) & (US$/unit) Table 182. Asia Anti-Obesity Prescription Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 183. Asia Anti-Obesity Prescription Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 184. Asia Anti-Obesity Prescription Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 185. Asia Anti-Obesity Prescription Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 186. Asia Anti-Obesity Prescription Sales by Country (2021-2026) & (k units) Table 187. Asia Anti-Obesity Prescription Sales by Country (2027-2032) & (k units) Table 188. Asia Anti-Obesity Prescription Sales Price by Country (2021-2026) & (US$/unit) Table 189. Asia Anti-Obesity Prescription Sales Price by Country (2027-2032) & (US$/unit) Table 190. Japan Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 191. South Korea Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 192. India Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 193. Australia Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 194. Taiwan Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 195. Southeast Asia Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 196. SAMEA Anti-Obesity Prescription Revenue by Type (2021-2026) & (US$ Million) Table 197. SAMEA Anti-Obesity Prescription Revenue by Type (2027-2032) & (US$ Million) Table 198. SAMEA Anti-Obesity Prescription Sales by Type (2021-2026) & (k units) Table 199. SAMEA Anti-Obesity Prescription Sales by Type (2027-2032) & (k units) Table 200. SAMEA Anti-Obesity Prescription Sales Price by Type (2021-2026) & (US$/unit) Table 201. SAMEA Anti-Obesity Prescription Sales Price by Type (2027-2032) & (US$/unit) Table 202. SAMEA Anti-Obesity Prescription Revenue by Application (2021-2026) & (US$ Million) Table 203. SAMEA Anti-Obesity Prescription Revenue by Application (2027-2032) & (US$ Million) Table 204. SAMEA Anti-Obesity Prescription Sales by Application (2021-2026) & (k units) Table 205. SAMEA Anti-Obesity Prescription Sales by Application (2027-2032) & (k units) Table 206. SAMEA Anti-Obesity Prescription Sales Price by Application (2021-2026) & (US$/unit) Table 207. SAMEA Anti-Obesity Prescription Sales Price by Application (2027-2032) & (US$/unit) Table 208. SAMEA Anti-Obesity Prescription Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 209. SAMEA Anti-Obesity Prescription Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 210. SAMEA Anti-Obesity Prescription Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 211. SAMEA Anti-Obesity Prescription Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 212. SAMEA Anti-Obesity Prescription Sales by Country (2021-2026) & (k units) Table 213. SAMEA Anti-Obesity Prescription Sales by Country (2027-2032) & (k units) Table 214. SAMEA Anti-Obesity Prescription Sales Price by Country (2021-2026) & (US$/unit) Table 215. SAMEA Anti-Obesity Prescription Sales Price by Country (2027-2032) & (US$/unit) Table 216. Brazil Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 217. Argentina Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 218. Chile Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 219. Colombia Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 220. Peru Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 221. Saudi Arabia Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 222. Israel Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 223. UAE Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 224. Turkey Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 225. Iran Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 226. Egypt Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Table 227. Key Raw Materials Table 228. Raw Materials Key Suppliers Table 229. Anti-Obesity Prescription Distributors List Table 230. Anti-Obesity Prescription Customers List Table 231. Research Programs/Design for This Report Table 232. Authors List of This Report Table 233. Secondary Sources Table 234. Primary Sources List of Figures Figure 1. Anti-Obesity Prescription Image Figure 2. Global Anti-Obesity Prescription Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-Obesity Prescription Market Size Share 2021 VS 2025 VS 2032 Figure 4. Lorcaserin Image Figure 5. Liraglutide Image Figure 6. Phentermine and Topiramate Image Figure 7. Orlistat Image Figure 8. Bupropion and Naltrexone Image Figure 9. Global Anti-Obesity Prescription Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Anti-Obesity Prescription Market Size Share 2021 VS 2025 VS 2032 Figure 11. E-Commerce Image Figure 12. Retail Pharmacies Image Figure 13. Hospital Pharmacies Image Figure 14. Global Anti-Obesity Prescription Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Anti-Obesity Prescription Revenue (2021-2032) & (US$ Million) Figure 16. Global Anti-Obesity Prescription Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 17. Global Anti-Obesity Prescription Revenue Market Share by Region: 2025 Versus 2032 Figure 18. Global Anti-Obesity Prescription Revenue Market Share by Region (2021-2032) Figure 19. Global Anti-Obesity Prescription Sales (2021-2032) & (k units) Figure 20. Global Anti-Obesity Prescription Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 21. Global Anti-Obesity Prescription Sales Market Share by Region (2021-2032) Figure 22. US & Canada & Mexico Anti-Obesity Prescription Sales YoY (2021-2032) & (k units) Figure 23. Europe Anti-Obesity Prescription Sales YoY (2021-2032) & (k units) Figure 24. China Anti-Obesity Prescription Sales YoY (2021-2032) & (k units) Figure 25. Asia (Excluding China) Anti-Obesity Prescription Sales YoY (2021-2032) & (k units) Figure 26. South America, Middle East and Africa Anti-Obesity Prescription Sales YoY (2021-2032) & (k units) Figure 27. Global Anti-Obesity Prescription Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 28. Global Anti-Obesity Prescription Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global Anti-Obesity Prescription Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Anti-Obesity Prescription Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Anti-Obesity Prescription Revenue Market Share by Type (2021-2032) Figure 33. Global Anti-Obesity Prescription Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 34. Global Anti-Obesity Prescription Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global Anti-Obesity Prescription Sales Market Share by Type (2021-2032) Figure 36. Global Anti-Obesity Prescription Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 37. Global Anti-Obesity Prescription Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Anti-Obesity Prescription Revenue Market Share by Application (2021-2032) Figure 39. Global Anti-Obesity Prescription Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 40. Global Anti-Obesity Prescription Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global Anti-Obesity Prescription Sales Market Share by Application (2021-2032) Figure 42. North America Anti-Obesity Prescription Revenue Share by Type (2021-2032) Figure 43. North America Anti-Obesity Prescription Sales Share by Type (2021-2032) Figure 44. North America Anti-Obesity Prescription Revenue Share by Application (2021-2032) Figure 45. North America Anti-Obesity Prescription Sales Share by Application (2021-2032) Figure 46. North America Anti-Obesity Prescription Revenue Share by Country (2021-2032) Figure 47. North America Anti-Obesity Prescription Sales Share by Country (2021-2032) Figure 48. Europe Anti-Obesity Prescription Revenue Share by Type (2021-2032) Figure 49. Europe Anti-Obesity Prescription Sales Share by Type (2021-2032) Figure 50. Europe Anti-Obesity Prescription Revenue Share by Application (2021-2032) Figure 51. Europe Anti-Obesity Prescription Sales Share by Application (2021-2032) Figure 52. Europe Anti-Obesity Prescription Revenue Share by Country (2021-2032) Figure 53. Europe Anti-Obesity Prescription Sales Share by Country (2021-2032) Figure 54. China Anti-Obesity Prescription Revenue Share by Type (2021-2032) Figure 55. China Anti-Obesity Prescription Sales Share by Type (2021-2032) Figure 56. China Anti-Obesity Prescription Revenue Share by Application (2021-2032) Figure 57. China Anti-Obesity Prescription Sales Share by Application (2021-2032) Figure 58. Asia Anti-Obesity Prescription Revenue Share by Type (2021-2032) Figure 59. Asia Anti-Obesity Prescription Sales Share by Type (2021-2032) Figure 60. Asia Anti-Obesity Prescription Revenue Share by Application (2021-2032) Figure 61. Asia Anti-Obesity Prescription Sales Share by Application (2021-2032) Figure 62. Asia Anti-Obesity Prescription Revenue Share by Country (2021-2032) Figure 63. Asia Anti-Obesity Prescription Sales Share by Country (2021-2032) Figure 64. SAMEA Anti-Obesity Prescription Revenue Share by Type (2021-2032) Figure 65. SAMEA Anti-Obesity Prescription Sales Share by Type (2021-2032) Figure 66. SAMEA Anti-Obesity Prescription Revenue Share by Application (2021-2032) Figure 67. SAMEA Anti-Obesity Prescription Sales Share by Application (2021-2032) Figure 68. SAMEA Anti-Obesity Prescription Revenue Share by Country (2021-2032) Figure 69. SAMEA Anti-Obesity Prescription Sales Share by Country (2021-2032) Figure 70. Anti-Obesity Prescription Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Anti-Obesity Prescription Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Lorcaserin
  • Liraglutide
  • Phentermine and Topiramate
  • Orlistat
  • Bupropion and Naltrexone
Applications
  • E-Commerce
  • Retail Pharmacies
  • Hospital Pharmacies
Companies covered
  • Akrimax Pharmaceuticals
  • Alpex Pharma
  • Arena Pharmaceuticals
  • Arrowhead Research
  • Bridge BioResearch
  • Compellis Pharmaceuticals
  • Yungjin Pharm
  • Zealand Pharma
  • Zydus Cadila

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Anti-Obesity Prescription Market by Type
  3. 1.2.1 Global Anti-Obesity Prescription Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Lorcaserin
  5. 1.2.3 Liraglutide
  6. 1.2.4 Phentermine and Topiramate
  7. 1.2.5 Orlistat
  8. 1.2.6 Bupropion and Naltrexone
  9. 1.3 Anti-Obesity Prescription Market by Application
  10. 1.3.1 Global Anti-Obesity Prescription Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 E-Commerce
  12. 1.3.3 Retail Pharmacies
  13. 1.3.4 Hospital Pharmacies
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Anti-Obesity Prescription Market Dynamics
  1. 2.1 Anti-Obesity Prescription Industry Trends
  2. 2.2 Anti-Obesity Prescription Industry Drivers
  3. 2.3 Anti-Obesity Prescription Industry Opportunities and Challenges
  4. 2.4 Anti-Obesity Prescription Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Anti-Obesity Prescription Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Anti-Obesity Prescription Revenue by Region
  3. 3.2.1 Global Anti-Obesity Prescription Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Anti-Obesity Prescription Revenue by Region (2021-2026)
  5. 3.2.3 Global Anti-Obesity Prescription Revenue by Region (2027-2032)
  6. 3.2.4 Global Anti-Obesity Prescription Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Anti-Obesity Prescription Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Anti-Obesity Prescription Sales by Region
  9. 3.4.1 Global Anti-Obesity Prescription Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Anti-Obesity Prescription Sales by Region (2021-2026)
  11. 3.4.3 Global Anti-Obesity Prescription Sales by Region (2027-2032)
  12. 3.4.4 Global Anti-Obesity Prescription Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Anti-Obesity Prescription Revenue by Manufacturers
  2. 4.1.1 Global Anti-Obesity Prescription Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Anti-Obesity Prescription Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Anti-Obesity Prescription Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Anti-Obesity Prescription Sales by Manufacturers
  6. 4.2.1 Global Anti-Obesity Prescription Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Anti-Obesity Prescription Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Anti-Obesity Prescription Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Anti-Obesity Prescription Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Anti-Obesity Prescription Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Anti-Obesity Prescription Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Anti-Obesity Prescription Manufacturers, Product Type & Application
  13. 4.7 Global Anti-Obesity Prescription Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Anti-Obesity Prescription Market CR5 and HHI
  16. 4.8.2 2025 Anti-Obesity Prescription Tier 1, Tier 2, and Tier 3
5 Anti-Obesity Prescription Market by Type
  1. 5.1 Global Anti-Obesity Prescription Revenue by Type
  2. 5.1.1 Global Anti-Obesity Prescription Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Anti-Obesity Prescription Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Anti-Obesity Prescription Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Anti-Obesity Prescription Sales by Type
  6. 5.2.1 Global Anti-Obesity Prescription Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Anti-Obesity Prescription Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Anti-Obesity Prescription Sales Market Share by Type (2021-2032)
  9. 5.3 Global Anti-Obesity Prescription Price by Type
6 Anti-Obesity Prescription Market by Application
  1. 6.1 Global Anti-Obesity Prescription Revenue by Application
  2. 6.1.1 Global Anti-Obesity Prescription Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Anti-Obesity Prescription Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Anti-Obesity Prescription Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Anti-Obesity Prescription Sales by Application
  6. 6.2.1 Global Anti-Obesity Prescription Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Anti-Obesity Prescription Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Anti-Obesity Prescription Sales Market Share by Application (2021-2032)
  9. 6.3 Global Anti-Obesity Prescription Price by Application
7 Company Profiles
  1. 7.1 Akrimax Pharmaceuticals
  2. 7.1.1 Akrimax Pharmaceuticals Company Information
  3. 7.1.2 Akrimax Pharmaceuticals Business Overview
  4. 7.1.3 Akrimax Pharmaceuticals Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Akrimax Pharmaceuticals Anti-Obesity Prescription Product Portfolio
  6. 7.1.5 Akrimax Pharmaceuticals Recent Developments
  7. 7.2 Alpex Pharma
  8. 7.2.1 Alpex Pharma Company Information
  9. 7.2.2 Alpex Pharma Business Overview
  10. 7.2.3 Alpex Pharma Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Alpex Pharma Anti-Obesity Prescription Product Portfolio
  12. 7.2.5 Alpex Pharma Recent Developments
  13. 7.3 Arena Pharmaceuticals
  14. 7.3.1 Arena Pharmaceuticals Company Information
  15. 7.3.2 Arena Pharmaceuticals Business Overview
  16. 7.3.3 Arena Pharmaceuticals Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Arena Pharmaceuticals Anti-Obesity Prescription Product Portfolio
  18. 7.3.5 Arena Pharmaceuticals Recent Developments
  19. 7.4 Arrowhead Research
  20. 7.4.1 Arrowhead Research Company Information
  21. 7.4.2 Arrowhead Research Business Overview
  22. 7.4.3 Arrowhead Research Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Arrowhead Research Anti-Obesity Prescription Product Portfolio
  24. 7.4.5 Arrowhead Research Recent Developments
  25. 7.5 Bridge BioResearch
  26. 7.5.1 Bridge BioResearch Company Information
  27. 7.5.2 Bridge BioResearch Business Overview
  28. 7.5.3 Bridge BioResearch Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Bridge BioResearch Anti-Obesity Prescription Product Portfolio
  30. 7.5.5 Bridge BioResearch Recent Developments
  31. 7.6 Compellis Pharmaceuticals
  32. 7.6.1 Compellis Pharmaceuticals Company Information
  33. 7.6.2 Compellis Pharmaceuticals Business Overview
  34. 7.6.3 Compellis Pharmaceuticals Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Compellis Pharmaceuticals Anti-Obesity Prescription Product Portfolio
  36. 7.6.5 Compellis Pharmaceuticals Recent Developments
  37. 7.7 Yungjin Pharm
  38. 7.7.1 Yungjin Pharm Company Information
  39. 7.7.2 Yungjin Pharm Business Overview
  40. 7.7.3 Yungjin Pharm Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Yungjin Pharm Anti-Obesity Prescription Product Portfolio
  42. 7.7.5 Yungjin Pharm Recent Developments
  43. 7.8 Zealand Pharma
  44. 7.8.1 Zealand Pharma Company Information
  45. 7.8.2 Zealand Pharma Business Overview
  46. 7.8.3 Zealand Pharma Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Zealand Pharma Anti-Obesity Prescription Product Portfolio
  48. 7.8.5 Zealand Pharma Recent Developments
  49. 7.9 Zydus Cadila
  50. 7.9.1 Zydus Cadila Company Information
  51. 7.9.2 Zydus Cadila Business Overview
  52. 7.9.3 Zydus Cadila Anti-Obesity Prescription Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Zydus Cadila Anti-Obesity Prescription Product Portfolio
  54. 7.9.5 Zydus Cadila Recent Developments
8 North America
  1. 8.1 North America Anti-Obesity Prescription Market Size by Type
  2. 8.1.1 North America Anti-Obesity Prescription Revenue by Type (2021-2032)
  3. 8.1.2 North America Anti-Obesity Prescription Sales by Type (2021-2032)
  4. 8.1.3 North America Anti-Obesity Prescription Price by Type (2021-2032)
  5. 8.2 North America Anti-Obesity Prescription Market Size by Application
  6. 8.2.1 North America Anti-Obesity Prescription Revenue by Application (2021-2032)
  7. 8.2.2 North America Anti-Obesity Prescription Sales by Application (2021-2032)
  8. 8.2.3 North America Anti-Obesity Prescription Price by Application (2021-2032)
  9. 8.3 North America Anti-Obesity Prescription Market Size by Country
  10. 8.3.1 North America Anti-Obesity Prescription Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Anti-Obesity Prescription Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Anti-Obesity Prescription Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Anti-Obesity Prescription Market Size by Type
  2. 9.1.1 Europe Anti-Obesity Prescription Revenue by Type (2021-2032)
  3. 9.1.2 Europe Anti-Obesity Prescription Sales by Type (2021-2032)
  4. 9.1.3 Europe Anti-Obesity Prescription Price by Type (2021-2032)
  5. 9.2 Europe Anti-Obesity Prescription Market Size by Application
  6. 9.2.1 Europe Anti-Obesity Prescription Revenue by Application (2021-2032)
  7. 9.2.2 Europe Anti-Obesity Prescription Sales by Application (2021-2032)
  8. 9.2.3 Europe Anti-Obesity Prescription Price by Application (2021-2032)
  9. 9.3 Europe Anti-Obesity Prescription Market Size by Country
  10. 9.3.1 Europe Anti-Obesity Prescription Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Anti-Obesity Prescription Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Anti-Obesity Prescription Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Anti-Obesity Prescription Market Size by Type
  2. 10.1.1 China Anti-Obesity Prescription Revenue by Type (2021-2032)
  3. 10.1.2 China Anti-Obesity Prescription Sales by Type (2021-2032)
  4. 10.1.3 China Anti-Obesity Prescription Price by Type (2021-2032)
  5. 10.2 China Anti-Obesity Prescription Market Size by Application
  6. 10.2.1 China Anti-Obesity Prescription Revenue by Application (2021-2032)
  7. 10.2.2 China Anti-Obesity Prescription Sales by Application (2021-2032)
  8. 10.2.3 China Anti-Obesity Prescription Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Anti-Obesity Prescription Market Size by Type
  2. 11.1.1 Asia Anti-Obesity Prescription Revenue by Type (2021-2032)
  3. 11.1.2 Asia Anti-Obesity Prescription Sales by Type (2021-2032)
  4. 11.1.3 Asia Anti-Obesity Prescription Price by Type (2021-2032)
  5. 11.2 Asia Anti-Obesity Prescription Market Size by Application
  6. 11.2.1 Asia Anti-Obesity Prescription Revenue by Application (2021-2032)
  7. 11.2.2 Asia Anti-Obesity Prescription Sales by Application (2021-2032)
  8. 11.2.3 Asia Anti-Obesity Prescription Price by Application (2021-2032)
  9. 11.3 Asia Anti-Obesity Prescription Market Size by Country
  10. 11.3.1 Asia Anti-Obesity Prescription Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Anti-Obesity Prescription Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Anti-Obesity Prescription Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Anti-Obesity Prescription Market Size by Type
  2. 12.1.1 SAMEA Anti-Obesity Prescription Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Anti-Obesity Prescription Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Anti-Obesity Prescription Price by Type (2021-2032)
  5. 12.2 SAMEA Anti-Obesity Prescription Market Size by Application
  6. 12.2.1 SAMEA Anti-Obesity Prescription Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Anti-Obesity Prescription Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Anti-Obesity Prescription Price by Application (2021-2032)
  9. 12.3 SAMEA Anti-Obesity Prescription Market Size by Country
  10. 12.3.1 SAMEA Anti-Obesity Prescription Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Anti-Obesity Prescription Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Anti-Obesity Prescription Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Anti-Obesity Prescription Value Chain Analysis
  2. 13.1.1 Anti-Obesity Prescription Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Anti-Obesity Prescription Production Mode & Process
  6. 13.2 Anti-Obesity Prescription Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Anti-Obesity Prescription Distributors
  9. 13.2.3 Anti-Obesity Prescription Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst